INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 43h ago
HOUSE PTR3h ago
SEC 13F3h ago
ROBINHOOD CHAIN3h ago
Public company

LENZLENZ Therapeutics, Inc.

CIK 0001815776

EDGAR filingsOpen in network
Disclosed transactions14
Buys / sells6 / 2
Max Insider Score57
Connections7with evidence

LENZ · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
50
CR
Chevallard Daniel R.Chief Financial Officer
LENZLENZ Therapeutics, Inc.
Open-market purchase
BUY$64K
7,500 sh
Mar 27, 2026Mar 30, 2026
traded Mar 27, 2026
+3dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2836 · Biological Products, (No Diagnostic Substances) · Nov 4, 2026
  • ← Insider ofevidence
    George Jeffrey P.Director · Mar 30, 2026
  • ← Insider ofevidence
    Schimmelpennink Evert B.Director, President, CEO and Secretary · Mar 30, 2026
  • ← Insider ofevidence
    Odrich MarcChief Medical Officer · Jan 6, 2026
57
SB
Schimmelpennink Evert B.Director, President, CEO and Secretary
LENZLENZ Therapeutics, Inc.
Open-market purchase
BUY
$251K
28.1K sh
Mar 27, 2026
Mar 30, 2026
traded Mar 27, 2026
+3d
SEC FORM 4

Evidence

51
GP
George Jeffrey P.Director
LENZLENZ Therapeutics, Inc.
Open-market purchase
BUY$50K
5,592 sh
Mar 27, 2026Mar 30, 2026
traded Mar 27, 2026
+3dSEC FORM 4

Evidence

5
OS
Olsson ShawnChief Commercial Officer
LENZLENZ Therapeutics, Inc.
Grant or award
A—
14.0K sh
Jan 2, 2026Jan 6, 2026
traded Jan 2, 2026
+4dSEC FORM 4

Evidence

9
OM
Odrich MarcChief Medical Officer
LENZLENZ Therapeutics, Inc.
Grant or award
A—
84.2K sh
Jan 2, 2026Jan 6, 2026
traded Jan 2, 2026
+4dSEC FORM 4

Evidence

9
OM
Odrich MarcChief Medical Officer
LENZLENZ Therapeutics, Inc.
Grant or award
A—
14.0K sh
Jan 2, 2026Jan 6, 2026
traded Jan 2, 2026
+4dSEC FORM 4

Evidence

5
OS
Olsson ShawnChief Commercial Officer
LENZLENZ Therapeutics, Inc.
Grant or award
A—
84.2K sh
Jan 2, 2026Jan 6, 2026
traded Jan 2, 2026
+4dSEC FORM 4

Evidence

16
OS
Olsson ShawnChief Commercial Officer
LENZLENZ Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$108K
4,212 sh
Nov 17, 2025Nov 19, 2025
traded Nov 17, 2025
+2dSEC FORM 4

Evidence

11
OS
Olsson ShawnChief Commercial Officer
LENZLENZ Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$21K
10.0K sh
Nov 17, 2025Nov 19, 2025
traded Nov 17, 2025
+2dSEC FORM 4

Evidence

7
OS
Olsson ShawnChief Commercial Officer
LENZLENZ Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
10.0K sh
Nov 17, 2025Nov 19, 2025
traded Nov 17, 2025
+2dSEC FORM 4

Evidence

20
OS
Olsson ShawnChief Commercial Officer
LENZLENZ Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$153K
5,788 sh
Nov 17, 2025Nov 19, 2025
traded Nov 17, 2025
+2dSEC FORM 4

Evidence

49
MW
Mccollum James WDirector
LENZLENZ Therapeutics, Inc.
Open-market purchase
BUY$239K
10.5K sh
Nov 7, 2025Nov 10, 2025
traded Nov 7, 2025
+3dSEC FORM 4

Evidence

46
CR
Chevallard Daniel R.Chief Financial Officer
LENZLENZ Therapeutics, Inc.
Open-market purchase
BUY$50K
2,178 sh
Nov 7, 2025Nov 7, 2025
traded Nov 7, 2025
+0dSEC FORM 4

Evidence

34
CR
Chevallard Daniel R.Chief Financial Officer
LENZLENZ Therapeutics, Inc.
Open-market purchase
BUY$454
20 sh
Nov 7, 2025Nov 7, 2025
traded Nov 7, 2025
+0dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Olsson ShawnChief Commercial Officer · Nov 19, 2025
  • ← Insider ofevidence
    Mccollum James WDirector · Nov 10, 2025
  • ← Insider ofevidence
    Chevallard Daniel R.Chief Financial Officer · Nov 7, 2025